The biotech sector remains in focus, specifically the COVID-19 vaccine market where Pfizer, BioNTech and Moderna are key players. An ongoing patent dispute between Pfizer and Moderna saw a partial victory for Moderna in UK trials. Furthermore, BioNTech's breast cancer precision drug trial is pitted against AstraZeneca. For its expansion efforts, BioNTech secured $145M from CEPI to bolster mRNA vaccine production in Africa. Expanding further into oncology, BioNTech targets a commercial debut in 2026. Meanwhile, the company reported a net loss of €315.1m in Q1 2024, partly from lower COVID-19 sales. The company is also facing a FDA delay for a cancer drug licensed from MediLink, adding challenges in a competitive market. Amid these factors, it is important to stay updated regarding different COVID-19 vaccine-related news and their impacts on the sector's leading companies.
BIONTECH News Analytics from Mon, 28 Aug 2023 07:00:00 GMT to Wed, 03 Jul 2024 13:26:53 GMT - Rating -3 - Innovation 7 - Information 8 - Rumor 5
